RXST250117P37500
- 4.63
- 0.000.00%
RxSight Newsroom
Insider Purchase: Director at $RXST (RXST) Buys 1,767 Shares
Needham Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $43
Express News | Rxsight Inc : Needham Cuts Target Price to $43 From $66
RxSight Is Maintained at Equal-Weight by Wells Fargo
Express News | Stifel Maintains Hold on RxSight, Lowers Price Target to $35
RxSight Shares Drop by 21% Following Disappointing Revenue Forecast
RxSight Analyst Ratings
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $35 to $70
Express News | Rxsight Inc : Wells Fargo Cuts Target Price to $40 From $42
RxSight: Balanced Outlook Amid Mixed Q4 Performance and Revised Valuation
RxSight's Promising Growth Fueled by Strong Market Performance and Strategic Expansion
Positive Outlook for RxSight: Strong Revenue and Margin Projections Justify Buy Rating
Needham Reiterates Buy on RxSight, Announces $66 Price Target
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Health Catalyst (HCAT) and Amicus (FOLD)
RxSight Sees Q4 Revenue $40.2M Vs. $40.4M Est; Sees FY 2024 Revenue ~$139.9M,Up 57% YoY
BTIG Sticks to Its Buy Rating for RxSight (RXST)
RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
Express News | Rxsight Outlook FY Gross Margin 71-73%
Express News | Rxsight Outlook FY Revenue USD 185-197 Million
Express News | Rxsight Q4 Revenue USD 40.2 Million Vs. IBES Estimate USD 40.4 Million